Topic UCB

Companies UCB

News UCB

• Cimzia shows positive top-line phase 3 results in axial spondyloarthritis and ankylosing spondylitis

  UCB announced positive top-line results from the phase 3 study designed to evaluate the efficacy and safety of certolizumab pegol in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases which includes ankylosing spondylitis (AS)."The populatio more

• UCB and Amgen Initiate Sclerostin Antibody Phase 3 program in patients with postmenopausal osteoporosis

  UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president of Resear more

• UCB and Oxford University announce new R&D partnership

  UCB Pharma and Oxford University agreed to collaborate on cutting-edge pharmaceutical research projects, enabling scientists from industry and academia to work together to develop medicines to treat serious diseases in immunology and neurology. These combined resources and expertise will give the be more

Publications UCB

• The use of sodium oxybate to treat narcolepsy

  Narcolepsy is a life-long neurodegenerative disorder that causes considerable impairment to quality of life. Until the 1970s, the treatment for one of the main symptoms, excessive daytime sleepiness, was restricted to stimulants, whereas the second core symptom, cataplexy, was treated with antidepre more

• Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies

  Although formation of urothelial carcinoma of the bladder (UCB) requires multiple steps and proceeds along divergent pathways, the underlying genetic and molecular determinants for each step and pathway remain undefined. By developing transgenic mice expressing single or combinatorial genetic alter more

• Mesenchymal stem cells from umbilical cord blood: parameters for isolation, characterization and adipogenic differentiation

  Isolation of mesenchymal stem cells (MSCs) from umbilical cord blood (UCB) from full-term deliveries is a laborious, time-consuming process that results in a low yield of cells. In this study we identified parameters that can be helpful for a successful isolation of UCB-MSCs. According to our findin more

Market studies UCB

• Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Ankylosing Spondylitis Therapeutics market. T more

• Belgium Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: Belgium, much like most of the other regional markets, is expected to post negative year-onyear (y-o-y) value growth in its 2012 pharmaceutical sales because of patent expirations and the tightening operating environment. As part of its fiscal austerity programme, the new government is com more

• Childhood Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Childhood Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Childhood Epilepsy Therapeutics market. The repor more

Websites UCB